FAGR Fagron SA

Disclosure of notification received from FMR LLC

Disclosure of notification received from FMR LLC

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET

Disclosure of notification received from FMR LLC

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC.

Notification by FMR LLC

  • On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the disclosure threshold of 3% upwards on 18 November 2024 as the result of the acquisition of voting securities or voting rights.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 18 November 2024, FMR LLC held a total of 3,300,143 voting rights. 2,242,195 voting rights are held by Fidelity Management & Research Company LLC, 773,303 voting rights are held by Fidelity Institutional Asset Management Trust Company, 0 voting rights are held by FMR Investment Management (UK) Limited, and 284,645 voting rights are held by FIAM LLC.
  • Based on the denominator of 73,228,904 (total number of voting rights), FMR LLC held 4.51% of the total number of voting rights on 18 November 2024.
  • Full chain of controlled undertakings through which the holding is effectively held is as follows:
    • Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC;
    • FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC;
    • FIAM Holdings LLC and Fidelity Management & Research Company LLC are controlled by FMR LLC;
    • FMR LLC is not a controlled entity.
  • The holdings attributed to the entities mentioned above arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company and Fidelity Management & Research Company LLC, each of which are entities that are subsidiaries of and controlled by FMR LLC. These entities are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.
  • The notification of FMR LLC can be viewed via this .



Further information

Karin de Jong

Chief Financial Officer

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
26/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Disclosure of notification received from FMR LLC

Disclosure of notification received from FMR LLC Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC. Notification by FMR LLC On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the disclosure threshold of 3% upwards on 18 Nov...

 PRESS RELEASE

Openbaarmaking van kennisgeving ontvangen van FMR LLC

Openbaarmaking van kennisgeving ontvangen van FMR LLC Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 26 november 2024 – 18u45 CET Openbaarmaking van kennisgeving ontvangen van FMR LLC Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van FMR LLC. Kennisgeving van FMR LLC Op 21 november 2024 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van Fidelity Management & Research Company LLC, een onderneming onder controle van FMR LLC,...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update November 2024 – Adding Azelis – Removing ...

With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...

Kristof Samoy ... (+3)
  • Kristof Samoy
  • Thomas Vranken
  • Wim Hoste
Thomas Vranken
  • Thomas Vranken

Fagron Model update: FY24 outlook

Following Fagron's 3Q24 update, we update our FY24 outlook to reach the upper end of the revenue guidance of € 850-870m. In the coming quarters and years, we expect sustained solid performance across business units, as the company continues to benefit from increased outsourcing of pharmaceutical compounding and its operational excellence initiatives. We reiterate our € 24 TP, reflecting 27% upside vs the current share price, hence reiterate our Buy rating.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch